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Abstract The amyloid peptide (Afl) of Alzheimer’s disease 
(AD) is produced by proteolytic cleavage of a larger precursor, 
the amyloid peptide precursor or APP. The discovery of 
pathogenic mutations in the APP gene provides strong evidence 
for the hypothesis that APP metabolism is involved in the 
etiology of AD. To study the metabolism of the protein, human 
APP has been expressed in several mammalian cell types. Insect 
ceils, infected by a recombinant baculovirus carrying the human 
APP sequence, also provide an interesting expression system 
because these cells do not produce endogenous APP. Baculo- 
virus-infected cells synthesize very high amounts of extracellular 
soluble APP, after cleavage of the transmembrane protein, as 
described for mammalian cells. However, we demonstrate here 
that insect cells do not produce Afl from APP. These results 
suggest that while the enzymatic activity needed for the 
production of soluble APP is conserved between insect and 
mammalian cells, the enzymes required for the production of Afl 
from APP are only expressed in mammalian cells. 
Xq words: Alzheimer’s disease; Amyloid peptide precursor 
(APP); AD; Baculovirus 
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1. Introduction 
Alzheimer’s disease (AD) is characterized by severe demen- 
ti.! related to a serious loss of neurons. The pathology is 
typified by deposits of fibrilar amyloid peptide in the brain 
p:s.renchyma and cerebrovasculature. The 3943 amino acid 
amyloid peptide, also named AP, results from the proteolytic 
cleavage of a larger precursor, the amyloid peptide precursor 
(APP) [I]. Different gene mutations have been reported to 
cause familial AD [2-81. The discovery of pathogenic muta- 
tions in the APP gene [2-61, which modify the cellular metab- 
011sm of the protein [9,10], provides strong evidence for the 
hypothesis that APP metabolism leading to altered AD pro- 
duction or deposition is an early event in the etiology of AD. 
The constitutive secretory pathway of APP delivers some of 
the precursor to the cell surface; proteolytic cleavage of the 
tr,tnsmembrane protein leads to the secretion of a large solu- 
bl,: ectodomain of the protein and the retention of a small 10 
ki)a C-terminal fragment within the membrane. APP is 
chaaved in the secretory pathway by a proteolytic activity 
te -med a-secretase [I I]. Since the a-secretase cleaves within 
the AP peptide, this secretion process precludes the produc- 
tion of AD, and is known as the non-amyloidogenic catabolic 
puthway of APP. Only some of the APP molecules are actu- 
aliy processed by this secretory pathway. Recent reports show 
that soluble AP can be detected in vitro in the extracellular 
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medium from a variety of cultured mammalian cells [12-141 as 
well as in vivo in the human cerebrospinal fluid [15]. The AP 
peptide is therefore produced by normal cellular metabolism 
using an amyloidogenic catabolic pathway. The two catabolic 
pathways of APP have been studied in several mammalian cell 
types, including polarized cells like Madin-Darby Canine Kid- 
ney cells [16-181 or neurons [ 191. Baculovirus-infected cells 
also provide an interesting expression system in which a lot 
of human APP can be produced and transformed into an 
extracellular soluble protein following a-secretase cleavage 
[20]. Although human APP is processed in baculovirus-in- 
fected cells by the non-amyloidogenic catabolic pathway, we 
demonstrate herein that insect cells are not able to produce 
the amyloid peptide from its precursor. 
2. Materials and methods 
The cDNA encoding the entire human APP695, or the same se- 
quence carrying missense mutations associated with familial Alzhei- 
mer’s disease in Sweden [4,21], was cloned in the pAcCL29 vector [22]. 
Insect cells, Spodoptera.fnrgiperda Sf21 or St9, at a density of 3 x lo6 
cells per 60 mm d&h were cbtransfected with 1 pg linear Autographa 
californica viral DNA (Invitrogen. San Diego. CA) and 5 ue of the 
recbmbinant plasmid, using the DbTMA transfectibn reageh; (Boeh- 
ringer Mannheim). Recombinant viruses were harvested 5 days post- 
transfection, purified and titered as described [23]. Sf9 cells culture 
and infection was subsequently carried out in IPL41 medium (Gibco) 
supplemented with 10% fetal calf serum. Different multiplicities of 
infection, from 1 to 10, were tested. 
Proteins from St9 cells or their culture medium were analyzed by 
SDS-PAGE and transferred to a nitrocellulose membrane for 45 min 
at 5 mA/cm2. The filter was blocked for 1 h with 5% non-fat dry milk 
in TBS (50 mM Tris-HCl, 150 mM NaCl, 0.5% Tween 20, pH 8.1) 
and incubated overnight at room temperature with the primary anti- 
body. Membranes were then incubated with a biotinylated goat anti- 
mouse antibody followed by a streptavidin-alkaline phosphate com- 
plex. The alkaline phosphate activity was detected with nitroblue te- 
trazolium and 5-bromo-4-chloro-3-indolyl phosphate. Western blot- 
ting was also performed using the ECL reagents and protocols from 
Amersham. In this case, proteins were blotted to polyvinylidene di- 
fluoride (PVDF) membranes. The primary antibody used to detect 
APP was the monoclonal 3H5 antibody at a dilution of l/500 of 
the ascite fluid. This antibody is raised against the extracellular anio- 
nic domain of APP [24]. For the detection of the C-terminal domain 
of APP, the ‘Jonas’ monoclonal antibody was used following the 
recommendations of the manufacturer (Boehringer Mannheim). This 
antibody is raised against the amino acids 643-695 of APP 695. The 
4G8 anti-A!3 monoclonal antibody was also used at a 115000 dilution 
of the ascite fluid [25]. This antibody is raised against the amino acids 
17-24 of AP. 
For metabolic labeling, Sf9 cells were incubated overnight in 5 ml 
of culture medium containing 70 yCi [35S]methionine (Amersham). 
Cells and culture media were then harvested and used for immuno- 
precipitation experiments, performed in a solubilisation buffer (25 
mM Tris-HCl, 0.5% Triton X100, 0.5% NP 40, pH 7.5), as previously 
described [ 131. The soluble cellular extracts or the culture media were 
first incubated for 1 h in the presence of 20 ~1 of protein A Sepharose 
precoated with rabbit anti-mouse IgG. After centrifugation, superna- 
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tant was recovered and incubated overnight at 4°C with the 22Cll 
monoclonal antibody raised against the N-terminal domain of APP 
[26], and 30 ~1 of protein A sepharose (Pharmacia) precoated with 
rabbit anti-mouse IgG. After centrifugation, the pellet was first 
washed twice with 10 mM Tris-HCI, 130 mM NaC1, 0.2% NP 40, 
2 mM EDTA. oH 7.5. then twice with 10 mM Tris-HCl. 500 mM 
NaCI, 0.2% Nk40, 2 &M EDTA, pH 7.5, and then finally’once with 
10 mM Tris-HCl pH 7.5. The immunoprecipitate was resuspended in 
Laemmli sample buffer and analyzed in SDS-PAGE. The AP peptide 
was immunoprecipitated using the SGY2134 antibody as described by 
Shoji et al. [13]. This rabbit polyclonal antiserum is raised against 
synthetic peptide AP 140. The SGY2134 antibody recognizes both 
full-length APP and AD peptide, but poorly detects soluble APP re- 
sulting from a-secretase cleavage. The- immunoprecipitates were ana- 
lvzed on l&16% Tris-Tricine SDS-PAGE. For both immunomecini- 
&ions, the gels were dried and autoradiographed. 
_ _ 
The internalization of APP was measured using the radiolabeled 
22Cll monoclonal antibody. The 22Cll monoclonal antibody was 
purified by immunoadsorption on a anti-mouse IgG column, and 
labeled by lz51 iodine (Amersham), to a specific radioactivity of 150 
cpm/ng of protein. Baculovirus-infected cells expressing human APP 
were incubated for 1 h at 0°C in their culture medium containing 10 
nM [‘2sI]22Cl 1 antibody. After 6 rapid washes with the culture med- 
ium, the cells were incubated 3 times for 5 min in acidic PBS (pH 2.5). 
In these experimental conditions, only part of the radiolabeled 22Cl I 
antibody was removed from the cell surface. The reincubation of the 
cells at 27°C before the acidic washes allowed the internalization of 
APP to be measured. 
3. Results 
A recombinant baculovirus encoding the human APP was 
constructed and used to infect Sl9 cells. The time course of 
APP expression was determined using immunoblotting analy- 
sis of both total cellular extracts and culture medium of in- 
fected cells (Fig. 1). The APP synthesis could be observed 
after 24 h of infection, and was maximal after 48 h (Fig. 1). 
No effect of the multiplicity of infection, ranging from 1 to 10, 
was observed (Fig. 1). For a longer period of time after in- 
fection, a lower expression of APP was observed. This could 
correspond to a degradation process of APP occurring in in- 
fected cells which release proteolytic enzymes as a result of cell 
lysis following baculovirus infection. Thus, a 2-day infection 
A. 
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Fig. 1. Baculovirus-infected SI9 cells (A) and their culture medium 
(B) were analysed by immunoblotting using the 3H5 monoclonal 
anti-APP antibody, different times after infection (h) at different 









Fig. 2. The culture medium (A) of St9 cells infected by a recombi- 
nant baculovirus carrying the human APP695 cDNA sequence was 
analysed by immunoblotting using the 3H5 (l), the 4G8 (2), and 
the Jonas (3) monoclonal antibodies. The cellular extracts (B) were 
analysed by immunoblotting using the Jonas (1,3) or the 4G8 (2,4) 
antibodies. ECL detection was performed for 20 s (1,2) or 7 min 
(3,4). 
was performed in further experiments. In these conditions, 
soluble extracellular APP was produced by baculovirus-in- 
fected cells and was detected by the 3H5 monoclonal antibody 
(Fig. 2A, lane 1). When the same extracellular APP was ana- 
lyzed by immunoblotting using the 4G8 and the Jonas anti- 
bodies, the upper band, but not the lower bands, was detected 
(Fig. 2A, lanes 2 and 3). This indicates that extracellular APP 
with the highest molecular weight contains the C-terminal 
domain of APP, including amino acids 17 to 24 of the AD 
peptide, and is not cleaved by a-secretase. Therefore, not all 
the extracellular soluble APP produced by baculovirus-in- 
fected cells results from the a-secretase cleavage. 
The full-length APP sequence was also detected in the cel- 
lular extracts from baculovirus infected cells analysed in West- 
ern blotting using the Jonas and the 4G8 antibodies (Fig. 2B, 
lanes 1 and 2). When the ECL detection time was increased, 
both antibodies were able to detect C-terminal fragments of 
APP, as previously described [20,27]. A 15 kDa fragment (Fig. 
2B, lanes 3 and 4) has been previously demonstrated to cor- 
respond to the C-terminal domain of APP resulting from the 
a-secretase cleavage [20]. Fragments with higher molecular 
weights are also detected, although in lower amounts, and 
are recognized by the 4G8 monoclonal antibody. These results 





F 3. 3. Radiolabeled Aj3 secreted by transfected CHO cells expres- 
sir;g the human APP695 was incubated for 16 h at 37°C in the cul- 
tu:‘e medium conditioned by CHO cells (1) or baculovirus-infected 
ce 1s (2), before immunoprecipitation with the SGY2134 anti-AP 
at tibody. 
cc nfirm that baculovirus-infected cells are able to produce C- 
teminal fragments of APP which are recognized by an anti- 
A 3 antibody. 
Since baculovirus-infected cells produce a lot of extracellu- 
la. human APP as well as amyloidogenic C-terminal frag- 
rn;nts, the production of soluble extracellular AD peptide 
w ts also investigated. After metabolic labeling of insect cells 
2‘. h after infection and immunoprecipitation with the 
SC iY2134 antibody, no AP peptide was detected in the culture 
medium (not shown). Because the replication of the baculo- 
vi :us induces cell lysis, with a concomitant release of proteo- 
ly ic activities in the extracellular medium, the absence of ex- 
tr,tcellular Al3 peptide could result from the extracellular 
degradation of the amyloid peptide. Such a degradation of 
A 3 peptide produced in vitro by proteases released by cul- 
tt,red cells has been previously described [28]. To test this 
hl pothesis, radiolabelled AP peptide secreted by transfected 
C IO cells was incubated for 16 h at 37°C in the culture 
medium conditioned by either CHO cells or baculovirus-in- 
fe:ted cells. After this incubation, the Al3 peptide was immu- 
n Iprecipitated using the SGY2134 antibody. The results pre- 
sented in Fig. 3 indicate that AP peptide was recovered from 
tl.: culture medium of both CHO cells and baculovirus-in- 
fe:ted cells. Therefore, the absence of A!3 in the culture med- 
iL n of baculovirus-infected cells does not result from the de- 
gradation of the amyloid peptide by insect cells. 
It has been previously demonstrated that the deletion of the 
C terminal intracellular region of APP very significantly in- 
h:3its APP internalization and precludes AP production in 
CI ltured cells [21,29,30]. The absence of AP in the culture 
m :dium of baculovirus-infected cells could therefore result 
fr )rn an alteration of the internalization process related to 
bi culovirus infection. To test this hypothesis, we have mea- 
st red the endocytic process in St9 cells, 24 h after baculovirus 
in ‘ection. The baculovirus itself was used as a marker of re- 
ce @or-mediated endocytosis, since it is well established that a 
b; culovirus must be taken up by receptor-mediated endocy- 
tcsis in order to infect a host cell [31]. A wild-type baculovirus 
w ts therefore used to infect St9 cells at a multiplicity of in- 
fe\:tion of 50, which allows infection of 100% of the cells. 24 h 
la er, the recombinant baculovirus carrying the human APP 
cI)NA sequence was added to Sf9 cells previously infected by 
th: wild-type virus, and the synthesis of APP was analyzed by 
in munoblotting analysis of the secreted proteins. The results 
presented in Fig. 4 indicate that the second infection of Sf9 
cells by the recombinant baculovirus leads to APP synthesis. 
The amount of APP recovered in the extracellular medium 
was actually very similar to that found when the two viruses 
were used in a co-infection experiment. APP internalization 
was more directly demonstrated by internalization of the 
22Cll anti-APP monoclonal antibody. 24 h after infection, 
baculovirus-infected cells expressing APP were incubated for 
1 h at 0°C in the presence of 10 nM of the [‘251]22C1 1 anti- 
APP monoclonal antibody. Following six washes with culture 
medium, the cells were dissolved in sodium deoxycholate, 
counted, and the protein content was measured using Brad- 
ford’s method. The non-specific binding of the 22Cll anti- 
body, measured on St9 cells infected by the wild-type baculo- 
virus, was subtracted. The specific binding of [1251]22C1 1 
antibody corresponded to 3367 f 401 cpm/mg protein (n = 2). 
After 1 h incubation at 0°C 42.6 + 3.5% (n = 2) of the radio- 
activity was resistant to acidic washes, suggesting that inter- 
nalization can occur in insect cells at 0°C. When baculovirus- 
infected cells expressing human APP were rewarmed for 1 h at 
27°C 68.9 ? 5.6% (n = 2) of the radioactivity became resistant 
to acidic washes, indicating a significant increase (P = 0.0298) 
of APP internalization. Therefore, the absence of AP produc- 
tion by St9 cells expressing APP does not result from the 
absence of internalization of cell surface APP. 
It has been recently demonstrated that the production of 
AP from APP carrying a double mutation associated with 
familial Alzheimer’s disease in Sweden is independent of the 
internalization of APP [21,32]. These results indicate that the 
cellular compartments and mechanisms involved in the pro- 
duction of AP from Swedish APP are different from those 
involved in the production of Al3 from the wild-type sequence. 
In order to study whether baculovirus-infected cells are able 
to produce AP from Swedish APP, a recombinant baculovirus 
carrying the double mutation associated with familial Alzhei- 
mer’s disease in Sweden was used to infect Sl9 cells. After 
metabolic labeling, the SGY2134 antibody was able to immu- 
noprecipitate full-length APP following expression of both 
wild-type (Fig. 5 lane 2) and mutated (Fig. 5 lane 3) APP 
sequences. However, the anti-AP antibody was unable to im- 
munoprecipitate the amyloid peptide from the culture medium 
of baculovirus-infected cells. The same SGY2134 serum was 
able to demonstrate the production of Al3 by transfected 
kDa 
2D5- 
1 2 3 
Fig. 4. The culture medium of St9 cells infected by a wild-type ba- 
culovirus (l), co-infected by both a wild-type and the recombinant 
baculovirus carrying the human APP695 cDNA sequence (2) or in- 
fected by the same recombinant virus 24 h after a first infection by 
the wild-type virus (3) was analysed by immunoblotting using the 
3H5 monoclonal antibody. 
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Fig. 5. The culture medium of CHO cells expressing human 
APP695 (1) or St9 cells infected by a recombinant baculovirus car- 
rying the wild-type human APP695 cDNA sequence (2) or the same 
sequence with a double mutation associated with familial Alzhei- 
mer’s disease in Sweden (3) was immunoprecipitated after metabolic 
labeling, using the SGY2134 anti-A!3 antibody. 
CHO cells which do not secrete the full-length APP (Fig. 5 
lane 1). 
4. Discussion 
Insect cells infected by a recombinant baculovirus carrying 
the APP cDNA sequence synthesize human APP found both 
in cells and in their culture medium, as previously described 
[20,27,33-361. Part of the extracellular soluble APP results 
from the cleavage of the transmembrane protein by a-secre- 
tase [20,27]. The amino acid sequence analysis of extracellular 
APP has demonstrated that, in both insect and mammalian 
cells, the cleavage of the precursor occurs at the same position 
[20]. In addition to a truncated APP obtained by a-secretase 
cleavage, APP containing the C-terminal domain of APP, in- 
cluding amino acids 17 to 24 of the amyloid peptide, is also 
detected in the extracellular medium of baculovirus-infected 
cells. The presence of the full-length APP in the extracellular 
medium could result from cell lysis induced by infection. 
In the cellular extract of baculovirus-infected cells produc- 
ing human APP, several C-terminal fragments of APP have 
been previously described [27]. In addition to a 15 kDa frag- 
ment corresponding to the C-terminal domain of APP result- 
ing from a-secretase cleavage, fragments are labeled by anti- 
AP antibodies and are long enough to contain the full-length 
sequence of AP. These fragments are therefore amyloidogenic. 
Although the baculovirus expression system produces APP 
and amyloidogenic fragments thereof, the Aj3 peptide can not 
be detected in either infected cells (not shown) or their culture 
medium. The absence of AP in the culture medium of bacu- 
lovirus-infected cells does not result from degradation of the 
peptide, since the amyloid peptide produced by CHO cells was 
not degraded by a further incubation at 37°C in the presence 
of medium conditioned by baculovirus-infected cells. During 
the late phase of St9 cell infection by a baculovirus, extensive 
viral DNA replication and baculovirus production occur. Cel- 
lular modifications observed during infection [31] could alter 
the internalization process. A decrease of internalization dur- 
ing the late phase of infection could explain the absence of AP 
production by Sf9 cells, since production of AP from human 
APP requires endocytosis [21,29,30]. However, we demon- 
strate here that 24 h after a first baculovirus infection, insect 
cells are still able to be infected by a second virus. In addition, 
internalization of APP is demonstrated by the use of a radi- 
olabeled anti-APP antibody. A significant internalization is 
observed even at 0°C suggesting that, in insect cells, the inter- 
nalization process is not completely inhibited at this tempera- 
ture. In the same way, a surface labeling by fluorescent neu- 
rotensin of Sl9 cells expressing the neurotensin receptor was 
observed only if the cells were incubated at -5°C [37]. Finally, 
baculovirus-infected cells are not able to produce AP from 
Swedish APP, although this production has been demon- 
strated to be independent of the internalization process 
[21,32]. 
All together, these results demonstrate that baculovirus-in- 
fected cells produce high amounts of soluble APP, part of it 
being cleaved by a-secretase. Although these results could 
indicate that a-secretase is conserved between insects and 
mammals, they probably confirm that a-secretase is highly 
non-specific. On the contrary, the N-terminal cleavage gener- 
ating the AP peptide appears to be mediated by a sequence- 
dependent protease [38]. Our results demonstrate that while 
baculovirus-infected cells are able to produce amyloidogenic 
C-terminal fragments of APP, they are not able to process 
these fragments into amyloid peptide. Therefore, insect cells 
could represent an interesting cellular model for the further 
identification of enzymatic activities involved in the genera- 
tion of Afi from its precursor. 
Acknowledgements: We thank S. Younkin and K.S. Kim for provid- 
ing the antibodies SGY2134 and 4G8, respectively. We also thank B. 
Tasiaux-Doumont for excellent technical assistance. This work was 
supported by grants from the Fund for Medical Scientific Research 
(Belgium), the Queen Elisabeth Medical Foundation (Belgium), and 
the Bioavenir Program with the participation of the French Ministry 
of Research and the French Ministry of Industry. J.N.O. is Research 
Associate of the National Fund for Scientific Research (Belgium). 
References 
[l] Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Mas- 
ters, C.L., Grzeschik, K.H., Multhaup, G., Beyreuther, K. and 
Muller-Hill, B. (1987) Nature 325, 733-736. 
[2] Chartier-Harlin, MC., Crawford, F., Houlden, H., Warren, A., 
Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., 
Hardy, J., et al. (1991) Nature 353, 844846. 
[3] Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Craw- 
ford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L. 
and Hardy, J. (1991) Nature 349, 704706. 
141 Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., _ _ 
Winblad, B. and Lannfelt, L. (1992) Nat. Genet. 1, 345-347. 
151 Murrell. J.. Farlow. M.. Ghetti. B. and Benson. M.D. (1991) 
L A 
Science ‘254, 97-99. 
\ I 
[6] Hendriks, L., van Duijn, C.M., Cras, P., Cruts, M., Van Hul, W., 
van Harskamp, F., Warren, A., McInnis, M.G., Antonarakis, 
SE., Martin, J.J. et al. (1992) Nat. Genet. 1, 218-221. 
[7] Sherington, R., Rogaev, E.I., Liang, Y., Rogaev, E.A., Levesque, 
G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T. et 
al. (1995) Nature 375, 754-760. 
[8] Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D.M., Oshi- 
ma, J., Peetingell, W.H., Yu, C., Jondro, P.D., Schmidt, S.D., 
Wang, K. et al. (1995) Science 269, 973-977. 
R Essalmani et al.IFEBS Letters 389 (1996) 157-161 
Citron, M., Oltersdorf, T., Haas, C., McConlogue, L., Hung, 
A.Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I. and Selkoe, 
D.J. (1992) Nature 360, 672-674. 
Cai, X.D., Golde, T.E. and Youkin, S.G. (1993) Science 259, 
514516. 
Esch, F.S., Keim, P.S., Beattie, E.C., Blather, R.W., Culwell, 
A.R.. Oltersdorf. T.. McClure. D. and Ward. P.J. (1990) Science 
248,112221124.’ 
I  
Haass, C., Schlossmacher, G., Hung, A.Y., Vigo-Pelfrey, C., 
Mellon, A., Ostaszewski, B.L., Lieberburg, I., Koo, E.H., 
Schenk, D., Teplow, B. et al. (1992) Nature 359, 322-325. 
Shoji, M., Golde, T.E., Ghiso, J., Cheung, T.T., Estus, S., Shaf- 
fer, L.M., Cai, X.D., McKay, D.M., Tintner, R., Frangione, B. 
and Younkin, S.G. (1992) Science 258, 126129. 
Busciglio, J., Gabuzda, D.H., Matsudaira, P. and Yankner, B.A. 
(1993) Proc. Natl. Acad. Sci. USA 90, 2092-2096. 
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Da- 
vis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, 
C. et al. (1992) Nature 359, 3255327. 
De Strooper, B., Craessaerrts, K., Dewachter, I., Moechars, D., 
Greeberg, B., Van Leuven, F. and Van Den Berghe, H. (1995) 
J. Biol. Chem. 270, 405884065. 
Haass. C.. Koo. E.H.. Tenlow. D. and Selkoe. D.J. (1994) Proc. 
Natl. Acad. Sci: USA91,‘15641568. ’ ’ 
Haass, C., Koo, E.H., Capell, A., Teplow, D.B. and Selkoe, D.J. 
(1995) J. Cell. Biol. 128, 537-547. 
De Strooper, B., Simons, M., Multhaup, G., Van Leuven, F., 
Beyreuther, K. and Dotti, C. (1995) EMBO J. 14, 49324938. 
Ramabhadran, T.V., Gandy, S.E., Ghiso, J., Czernik, A.J., Fer- 
ris, D., Bhasin, R., Goldgaber, D., Frangione, B. and Greengard, 
P. (1993) J. Biol. Chem. 268. 2009-2012. 
Essalmahi, R., Macq, A.F., Mercken, L. and Octave, J.N. (1995) 
Biochem. Biophys. Res. Commun. 218, 89-96. 
Livingstone, C. and Jones, I. (1989) Nucl. Acid Res. 17, 2366. 
Summers. M.D. and Smith. G.E. (1987) A Manual of Methods 
for Baculovirus Vectors and Insect‘ Cell’Procedures, Texas Agri- 
cultural Experiment Station Bulletin no. 1555. 
Philippe, B., Brion, J.P., Macq, A.F. and Octave, J.N. (1993) 
Neurorep. 5, 289-292. 
161 
[25] Kim, KS., Miller, D.L., Sapienza, V.G., Chen, C.J., Bai, C., 
Grunke-Iqbal, I., Currrie, J.R. and Visniewski, H.M. (1988) Neu- 
rosci. Res. Commun. 2, 121-130. 
[26] Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, M., 
Masters, CL. and Beyreuther, K. (1989) Cell 57, 115-126. 
[27] Gandy, S.E., Bhasin, R., Ramabhadran, T.V., Koo, E.H., Proce, 
D.L., Goldgaber, D. and Greengard, P. (1992) J. Neurochem. 58, 
383-386. 
[28] Naidu, A., Quon, D. and Cordell, B. (1995) J. Biol. Chem. 270, 
136991374. 
[29] Le Blanc, A. and Gambetti, P. (1994) Biochim. Biophys. Res. 
Commun. 204, 1371-1380. 
[30] Koo, E.H. and Squazzo, S.L. (1994) J. Biol. Chem. 269, 17386- 
17389. 
[31] Knudson, D.L. and Harrap, K.A. (1976) J. Virol. 17, 254268. 
[32] Haass, C., Lemere, C.A., Capell, A., Citron, M., Seubert, P., 
Schenk, D., Lannfelt, L. and Selkoe, D.J. (1995) Nature Med. 
1, 1291-1296. 
[33] Bhasin, R., Van Nostrand, W.E., Saitoh, T., Donets, M.A., 
Barnes, E.A., Quitschke, W.W. and Goldgaber, D. (1991) Proc. 
Natl. Acad. Sci. USA 88, 10307-10311. 
[34] Currie, J.R., Ramakrishna, N., Burrage, T.G., Hwang, M.C., 
Potempska, A., Miller, D.L., Mehta, P.D., Kim, K.S. and Wis- 
niewski, H.M. (1991) J. Neurosci. Res. 30, 687-698. 
[35] Knops, J., Johnson-Wood, K., Schenk, D.B., Sinha, S., Lieber- 
burg, I. and McConlogue, L. (1991) J. Biol. Chem. 266, 72855 
7290. 
[36] Lowery, D.E., Pastemack, J.M., Gonzalez-DeWhitt, P.A., 
Zurcher-Neely, H., Tomich, C.C., Altman, R.A., Fairbanks, 
M.B., Heinrikson, R.L., Younkin, S.G. and Greenberg, B.D. 
(1991) J. Biol. Chem. 266, 19842219850. 
[37] Faure, M.P., Alonson, A., Nouel, D., Gaudriault, G., Dennis, 
M., Vincent, J.P. and Beaudet, A. (1995) J. Neurosci. 15, 4140- 
4147. 
[38] Citron, M.. Teplow, D.B. and Selkoe, D.J. (1995) Neuron 14, 
661-670. 
